Recent years have witnessed significant developments in the field of diabetes treatment, with a particular focus on GLP-1 receptor agonists. Among these novel therapies, retatrutide and trizepatide are emerging as https://stevesqqo354729.jts-blog.com/37710995/novel-therapeutic-targets-in-diabetes-retatrutide-and-trizepatide